摘要
铜绿假单胞菌是慢性肺囊性纤维化患者的主要致病菌,目前临床主要应用抗生素疗法,但是随着铜绿假单胞菌生物膜的形成,其对抗生素的耐药性越来越高,从而限制了抗生素的治疗效果.近年来,人们对其他新疗法进行不断地探索,希望能用来辅助抗生素治疗.下面主要对铜绿假单胞菌生物膜的耐药机制及治疗进展进行介绍.
Pseudomonas aeruginosa,an opportunistic gram-negative bacterium,is a major burden for individuals suffering from cystic fibrosis.Currently,antibiotics are the main drugs to treat infetions.With the formation of Pseudomonas aeruginosa biofilm,the rate of resistance to antibiotics is much higher so that the curative effect is not optimistic.In recent years,people are constantly exploring new therapies which will be adjunctive to antibiotic therapy.In this review,we explain the mechanism of multidrug resistance and provide an overview of new directions for treatment of chronic Pseudomonas aeruginosa infections.
出处
《国际呼吸杂志》
2014年第10期770-775,共6页
International Journal of Respiration
关键词
铜绿假单胞菌
生物膜
耐药性
治疗
Pseudomonas aeruginosa
Biofilm
Antibiotic resistance
Therapeutics
